Claire Navarro

Claire Navarro

Auto-generated profile, based on publicly available information

Claire Navarro

Aix Marseille Univ, INSERM, MMG, Marseille, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2003 in Science
Verified
Journal Article
Closed access
PDF file
ASAnnachiara De Sandre-Giovannoli
Annachiara De Sandre-Giovannoli
RBRafaëlLe Bernard
RafaëlLe Bernard
PCPierre Cau
Pierre Cau
CNClaire Navarro
Claire Navarro
JAJeanne Amiel
Jeanne Amiel
NLNicolas Levy
Nicolas Levy

26 October 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FOFernando G. Osorio
Fernando G. Osorio
CNClaire L. Navarro
Claire L. Navarro
JCJuan Cadiñanos
Juan Cadiñanos
IMIsabel C. Lopez Mejia
Isabel C. Lopez Mejia
PQPedro M. Quirós
Pedro M. Quirós
CLCarlos López-Otín
Carlos López-Otín
Hutchinson-Gilford progeria syndrome (HGPS) is caused by a point mutation in the LMNA gene that activates a cryptic donor splice site and yields a truncated form of prelamin A called progerin. Small amounts of progerin are also produced during normal aging. Studies with mouse models of HGPS have allowed the recent development of the first therapeutic approaches for this disease. However, none of these earlier works have addressed the aberrant and pathogenic LMNA splicing observed in HGPS patients because of the lack of an appropriate mouse model. Here, we report a genetically modified mouse strain that carries the HGPS mutation. These mice accumulate progerin, present histological and transcriptional alterations characteristic of progeroid models, and phenocopy the main clinical manifestations of human HGPS, including shortened life span and bone and cardiovascular aberrations. Using this animal model, we have developed an antisense morpholino–based therapy that prevents the pathogenic Lmna splicing, markedly reducing the accumulation of progerin and its associated nuclear defects. Treatment of mutant mice with these morpholinos led to a marked amelioration of their progeroid phenotype and substantially extended their life span, supporting the effectiveness of antisense oligonucleotide–based therapies for treating human diseases of accelerated aging.

29 June 2008 in Nature Medicine
Verified
Journal Article
Closed access
IVIgnacio Varela
Ignacio Varela
SPSandrine Pereira
Sandrine Pereira
AUAlejandro P Ugalde
Alejandro P Ugalde
CNClaire L Navarro
Claire L Navarro
MSMaría F Suárez
María F Suárez
CLCarlos López-Otín
Carlos López-Otín

18 August 2004 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CNClaire L. Navarro
Claire L. Navarro
ASAnnachiara De Sandre-Giovannoli
Annachiara De Sandre-Giovannoli
RBRafaëlle Bernard
Rafaëlle Bernard
IBIrène Boccaccio
Irène Boccaccio
ABAmandine Boyer
Amandine Boyer
NLNicolas Levy
Nicolas Levy
Restrictive dermopathy (RD), also called tight skin contracture syndrome (OMIM 275210), is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance. We explored nine fetuses/newborns children with RD. Two were found to have an heterozygous splicing mutation in the LMNA gene, leading to the complete or partial loss of exon 11 in mRNAs encoding Lamin A and resulting in a truncated Prelamin A protein. Lamins are major constituents of the nuclear lamina, a filamentous meshwork underlying the inner nuclear envelope. In the other seven patients, a unique heterozygous insertion leading to the creation of a premature termination codon was identified in the gene ZMPSTE24, also known as FACE-1 in human. This gene encodes a metalloproteinase specifically involved in the post-translational processing of Lamin A precursor. In all patients carrying a ZMPSTE24 mutation, loss of expression of Lamin A as well as abnormal patterns of nuclear sizes and shapes and mislocalization of Lamin-associated proteins was evidenced. Our results indicate that a common pathogenetic pathway, involving defects of the nuclear lamina and matrix, is involved in all RD cases. RD is thus one of the most deleterious laminopathies identified so far in humans caused by (primary or secondary) A-type Lamin defects and nuclear structural and functional alterations.

20 April 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CNClaire L. Navarro
Claire L. Navarro
JCJuan Cadiñanos
Juan Cadiñanos
ASAnnachiara De Sandre-Giovannoli
Annachiara De Sandre-Giovannoli
RBRafaëlle Bernard
Rafaëlle Bernard
SCSébastien Courrier
Sébastien Courrier
NLNicolas Levy
Nicolas Levy
Restrictive dermopathy (RD) is characterized by intrauterine growth retardation, tight and rigid skin with prominent superficial vessels, bone mineralization defects, dysplastic clavicles, arthrogryposis and early neonatal death. In two patients affected with RD, we recently reported two different heterozygous splicing mutations in the LMNA gene, leading to the production and accumulation of truncated Prelamin A. In other patients, a single nucleotide insertion was identified in ZMPSTE24. This variation is located in a homopolymeric repeat of thymines and introduces a premature termination codon. ZMPSTE24 encodes an endoprotease essential for the post-translational cleavage of the Lamin A precursor and the production of mature Lamin A. However, the autosomal recessive inheritance of RD suggested that a further molecular defect was present either in the second ZMPSTE24 allele or in another gene involved in Lamin A processing. Here, we report new findings in RD linked to ZMPSTE24 mutations. Ten RD patients were analyzed including seven from a previous series and three novel patients. All were found to be either homozygous or compound heterozygous for ZMPSTE24 mutations. We report three novel ‘null’ mutations as well as the recurrent thymine insertion. In all cases, we find a complete absence of both ZMPSTE24 and mature Lamin A associated with Prelamin A accumulation. Thus, RD is either a primary or a secondary laminopathy, caused by dominant de novo LMNA mutations or, more frequently, recessive null ZMPSTE24 mutations, most of which lie in a mutation hotspot within exon 9. The accumulation of truncated or normal length Prelamin A is, therefore, a shared pathophysiological feature in recessive and dominant RD. These findings have an important impact on our knowledge of the pathophysiology in Progeria and related disorders and will help direct the development of therapeutic approaches.

1 July 2012 in Cell Reports
Verified
Journal Article
Open access
XNXavier Nissan
Xavier Nissan
SBSophie Blondel
Sophie Blondel
CNClaire Navarro
Claire Navarro
YMYves Maury
Yves Maury
CDCécile Denis
Cécile Denis
MPMarc Peschanski
Marc Peschanski
One puzzling observation in patients affected with Hutchinson-Gilford progeria syndrome (HGPS), who overall exhibit systemic and dramatic premature aging, is the absence of any conspicuous cognitive impairment. Recent studies based on induced pluripotent stem cells derived from HGPS patient cells have revealed a lack of expression in neural derivatives of lamin A, a major isoform of LMNA that is initially produced as a precursor called prelamin A. In HGPS, defective maturation of a mutated prelamin A induces the accumulation of toxic progerin in patient cells. Here, we show that a microRNA, miR-9, negatively controls lamin A and progerin expression in neural cells. This may bear major functional correlates, as alleviation of nuclear blebbing is observed in nonneural cells after miR-9 overexpression. Our results support the hypothesis, recently proposed from analyses in mice, that protection of neural cells from progerin accumulation in HGPS is due to the physiologically restricted expression of miR-9 to that cell lineage.